ACUTE MYELOID LEUKEMIA WITH T(9;11)(P22.3;Q23.3); MLLT3-KMT2A

Clinical trials for ACUTE MYELOID LEUKEMIA WITH T(9;11)(P22.3;Q23.3); MLLT3-KMT2A explained in plain language.

Never miss a new study

Get alerted when new ACUTE MYELOID LEUKEMIA WITH T(9;11)(P22.3;Q23.3); MLLT3-KMT2A trials appear

Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA WITH T(9;11)(P22.3;Q23.3); MLLT3-KMT2A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New hope for older leukemia patients ineligible for harsh chemo

Disease control Ongoing

This early-stage study is testing the safety and best dose of a new drug, nintedanib, when combined with an existing drug, azacitidine. It is for older adults with a specific type of acute myeloid leukemia (AML) who are not candidates for or choose not to have intensive chemother…

Matched conditions: ACUTE MYELOID LEUKEMIA WITH T(9;11)(P22.3;Q23.3); MLLT3-KMT2A

Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control

Last updated Apr 03, 2026 14:43 UTC

ACUTE MYELOID LEUKEMIA WITH T(9;11)(P22.3;Q23.3); MLLT3-KMT2A

Get alerted when new ACUTE MYELOID LEUKEMIA WITH T(9;11)(P22.3;Q23.3); MLLT3-KMT2A trials appear

New hope for older leukemia patients ineligible for harsh chemo